ECO Animal Health expects revenue in line with current market expectations

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health market has provided an update on its operations in China.

The pork price in China has increased from less than RMB12/kg in early October 2021 to over RMB18/kg in early December 2021 before settling between RMB15/kg and RMB16/kg in early January 2022. Whilst the improvement in the pork price has resulted in improved trading conditions for pork producers, the commodity price continues to be volatile and producers remain cautious. Consequently, sales of Aivlosin® during the first three quarters of our financial year are subdued compared to the same period last year. However, revenue generated elsewhere in the Group continues in line with the prior year and, overall, the Board expects to report full year revenue in line with current market expectations. Cash repatriation from China has progressed as planned with both the royalty payment and dividend (totalling £4.6 million) having been received by ECO. Additionally, ECO has used some of its cash in its wholly owned Chinese subsidiary to assist with non-China cashflows and provide greater headroom for the ECO Group.

ECO is also exploring the possibility of increasing its banking facilities to provide greater flexibility to support ECO’s growth plans.

Appointment of Joint Broker and Capital Markets Day

As part of the development of the ECO Group, the Board of Directors has appointed Investec Bank plc (“Investec”) as a joint broker with immediate effect.  Singer Capital Markets (“SingerCM”) is retained as Nominated Advisor and joint broker and Peel Hunt LLP continues as joint broker (“Peel Hunt”).

ECO Animal Health plans to hold a Capital Markets Day at 9.00 a.m. on 26 January 2022. It is currently expected that the meeting will be held virtually to comply with current Covid-19 guidelines. Planning is underway and Investec, SingerCM and Peel Hunt will confirm participation arrangements in due course. The meeting will aim to provide insight into the ECO Group’s research and new product development activities.

Marc Loomes, ECO Animal Health CEO said:

“The pork commodity price in China is an important cornerstone to our business and we look forward to a steady recovery in that market. Despite difficult market conditions for the business in China, the Board expects, overall, to be reporting full year revenue in line with market expectations.”

“ECO started a programme of significant R&D investment in vaccines about four years ago and, notwithstanding that the programme is on-going, we have seen meaningful progress. We look forward to sharing some exciting insights and providing further details of the potential commercial value that exists within our new product development pipeline to existing and potential investors, analysts and media at the upcoming Capital Markets Day.” 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
ECO Animal Health Group plc

More articles like this

ECO Animal Health Group plc

ECO Animal Health disposes of ECOmectin® to ACME for €1.3m

ECO Animal Health Group plc (LON:EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, has announced the disposal of ECOmectin® Horsepaste to ACME Drugs S.r.l in Italy,

ECO Animal Health Group plc

ECO Animal Health ECOVAXXIN® trademark approved by the EU

ECO Animal Health Group plc (LON:EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, has announced that the ECOVAXXIN® trademark has been approved by the European

ECO Animal Health Group plc

ECO Animal Health completes sale of freehold properties

ECO Animal Health Group plc (LON:EAH) has announced that on 5 January 2024 the Company completed the sale of its freehold property in New Malden, Surrey.  This was the former registered office of the Company and following

ECO Animal Health Group plc

ECO Animal Health to host two Capital Markets events

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that it will be hosting two Capital Markets events focused on progress and

ECO Animal Health Group plc

ECO Animal Health Group Retail Investor Presentation

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, will be hosting a Capital Markets Day presentation for retail investors focusing on progress

ECO Animal Health Group plc

ECO Animal Health AGM to be held on Thursday 7 September 2023

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that the Company is today posting to shareholders notice of the Company’s Annual

ECO Animal Health Group plc

ECO Animal Health Group revenue ahead of market expectations

ECO Animal Health Group plc (LON:EAH) have today provided final results for the year ended 31 March 2023. HIGHLIGHTS Financial ·      Revenue and adjusted EBITDA ahead of market expectations ·      Group sales increased by 4% to £85.3m, driven primarily